Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01248130 · ClinicalTrials.gov registry record · Phase 2
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01248130: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01248130 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01248130, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary aim of this study is to examine the efficacy and tolerability of short-term omega-3 fatty acids monotherapy in youth with Autism Spectrum Disorders (ASD). The investigators hypothesize that Omega-3 fatty acids will be efficacious in improving the core and associated features of ASD in youth, and that Omega-3 fatty acids monotherapy will be safe and well tolerated by youth with ASD. The secondary aim of this study is to examine the neuropsychological effect of Omega-3 fatty acids monotherapy in youth with ASD. The investigators hypothesize that omega-3 fatty acids will be efficacious in improving cognitive functions in youth with ASD.
Interventions
- DRUG Omega-3 Fatty Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01248130
The ClinicalTrials.gov registry entry for NCT01248130 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omega-3 Fatty Acid is the first listed.
NCT01248130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01248130 about?
NCT01248130 is a clinical study titled "Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders". The primary aim of this study is to examine the efficacy and tolerability of short-term omega-3 fatty acids monotherapy in youth with Autism Spectrum Disorders (ASD). The investigators hypothesize that Omega-3 fatty acids will be efficacious in improving the core and associated features of ASD in yo...
What is the current status of trial NCT01248130?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2009-11. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01248130?
The interventions under investigation include: Omega-3 Fatty Acid (DRUG).
Who is sponsoring clinical trial NCT01248130?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.